SEC Form 4 · accession 0001209191-18-049785
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Sep 4, 2018
Accepted (ET)
Sep 6, 2018 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 4, 2018 | M | 7,000 | $5.5004 | A | 31,905 | D | |
| Common StockF2 | Sep 4, 2018 | S | 2,422 | $165.5288 | D | 29,483 | D | |
| Common StockF3 | Sep 4, 2018 | S | 2,083 | $166.5008 | D | 27,400 | D | |
| Common StockF4 | Sep 4, 2018 | S | 1,070 | $167.2986 | D | 26,330 | D | |
| Common StockF5 | Sep 4, 2018 | S | 1,425 | $168.2464 | D | 24,905 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $5.5004 | Sep 4, 2018 | M | 7,000 | D | — | Jan 16, 2023 | Common Stock | 7,000 | 36,951 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.
- F2The range in prices for the transaction reported on this line was $165.00 to $165.95. The average weighted price was $165.5288. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The range in prices for the transaction reported on this line was $166.00 to $166.95. The average weighted price was $166.5008. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The range in prices for the transaction reported on this line was $167.00 to $167.75. The average weighted price was $167.2986. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5The range in prices for the transaction reported on this line was $168.10 to $168.50. The average weighted price was $168.2464. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.